liu.seSök publikationer i DiVA
Ändra sökning
RefereraExporteraLänk till posten
Permanent länk

Direktlänk
Referera
Referensformat
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Annat format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annat språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf
Health Economic Evaluations of Screening Programs - Applications and Method Improvements
Linköpings universitet, Institutionen för medicin och hälsa, Avdelningen för hälso- och sjukvårdsanalys. Linköpings universitet, Medicinska fakulteten.
2017 (Engelska)Doktorsavhandling, sammanläggning (Övrigt vetenskapligt)
Abstract [en]

Screening to detect diseases early is attractive as it can improve the prognosis and decrease costs, but it is often a problematic concept and there are several pitfalls. Many healthy individuals have to be investigated to avoid a disease in a few, which results in a dilemma because to save a few, many are exposed to a procedure that could potentially harm them. Other examples of problems associated with screening are latent diseases and over-treating. The question of optimal design of a screening program is another source of uncertainty for decision-makers, as a screening program may potentially be implemented in very different ways. This highlights the need for structured analyses that weigh benefits against the harms and costs that occur as consequences of the screening.

The aim of this thesis is, therefore, to explore, develop and implement methods for health economic evaluations of screening programs. This is done to identify problems and suggest solutions to improve future evaluations and in extension policy making.

This aim was analysed using decision analytic cost-effectiveness analyses constructed as Markov models. These are well-suited for this task given the sequential management approach where all relevant data are unlikely to come from a single source of evidence. The input data were in this thesis obtained from the published literature and were complemented with data from Swedish registries and the included case studies. The case studies were two different types of screening programs; a program of screening for unknown atrial fibrillation and a program to detect colorectal cancer early. Further, the implementation of treatment with thrombectomy and novel oral anticoagulants were used to illustrate how factors outside the screening program itself have an impact on the evaluations.

As shown by the result of the performed analyses, the major contribution of this thesis was that it provided a simple and systematic approach for the economic evaluation of multiple screening designs to identify an optimal design.

In both the included case studies, the screening was considered costeffective in detecting the disease; unknown atrial fibrillation and colorectal cancer, respectively. Further, the optimal way to implement these screening programs is dependent on the threshold value for cost-effectiveness in the health care sector and the characteristics of the investigated cohort. This is because it is possible to gain increasingly more health benefits by changing the design of the screening program, but that the change in design also results in higher marginal costs. Additionally, changes in the screening setting were shown to be important as they affect the cost-effectiveness of the screening. This implies that flexible modelling with continuously updated models are necessary for an optimal resource allocation.

Ort, förlag, år, upplaga, sidor
Linköping: Linköping University Electronic Press, 2017. , s. 84
Serie
Linköping University Medical Dissertations, ISSN 0345-0082 ; 1578
Nationell ämneskategori
Hälso- och sjukvårdsorganisation, hälsopolitik och hälsoekonomi
Identifikatorer
URN: urn:nbn:se:liu:diva-141556DOI: 10.3384/diss.diva-141556ISBN: 9789176854914 (tryckt)OAI: oai:DiVA.org:liu-141556DiVA, id: diva2:1145702
Disputation
2017-10-06, Belladonna, Campus US, Linköping, 13:00 (Engelska)
Opponent
Handledare
Tillgänglig från: 2017-09-29 Skapad: 2017-09-29 Senast uppdaterad: 2017-09-29Bibliografiskt granskad
Delarbeten
1. Cost-effectiveness of high-sensitivity faecal immunochemical test and colonoscopy screening for colorectal cancer
Öppna denna publikation i ny flik eller fönster >>Cost-effectiveness of high-sensitivity faecal immunochemical test and colonoscopy screening for colorectal cancer
Visa övriga...
2017 (Engelska)Ingår i: British Journal of Surgery, ISSN 0007-1323, E-ISSN 1365-2168, Vol. 104, nr 8, s. 1078-1086Artikel i tidskrift (Refereegranskat) Published
Abstract [en]

Background: Colorectal cancer screening can decrease morbidity and mortality. However, there are widespread differences in the implementation of programmes and choice of strategy. The primary objective of this study was to estimate lifelong costs and health outcomes of two of the currently most preferred methods of screening for colorectal cancer: colonoscopy and sensitive faecal immunochemical test (FIT). Methods: A cost-effectiveness analysis of colorectal cancer screening in a Swedish population was performed using a decision analysis model, based on the design of the Screening of Swedish Colons (SCREESCO) study, and data from the published literature and registries. Lifelong cost and effects of colonoscopy once, colonoscopy every 10 years, FIT twice, FIT biennially and no screening were estimated using simulations. Results: For 1000 individuals invited to screening, it was estimated that screening once with colonoscopy yielded 49 more quality-adjusted life-years (QALYs) and a cost saving of (sic)64 800 compared with no screening. Similarly, screening twice with FIT gave 26 more QALYs and a cost saving of (sic)17 600. When the colonoscopic screening was repeated every tenth year, 7 additional QALYs were gained at a cost of (sic)189 400 compared with a single colonoscopy. The additional gain with biennial FIT screening was 25 QALYs at a cost of (sic)154 300 compared with two FITs. Conclusion: All screening strategies were cost-effective compared with no screening. Repeated and single screening strategies with colonoscopy were more cost-effective than FIT when lifelong effects and costs were considered. However, other factors such as patient acceptability of the test and availability of human resources also have to be taken into account.

Ort, förlag, år, upplaga, sidor
WILEY, 2017
Nationell ämneskategori
Hälso- och sjukvårdsorganisation, hälsopolitik och hälsoekonomi
Identifikatorer
urn:nbn:se:liu:diva-139394 (URN)10.1002/bjs.10536 (DOI)000403158800015 ()28561259 (PubMedID)
Anmärkning

Funding Agencies|SCREESCO; Regionala Cancer-centrum i samverkan; Swedish Cancer Foundation; Karolinska Institute

Tillgänglig från: 2017-08-24 Skapad: 2017-08-24 Senast uppdaterad: 2018-04-16
2. Cost-effectiveness of mass screening for untreated atrial fibrillation using intermittent ECG recording
Öppna denna publikation i ny flik eller fönster >>Cost-effectiveness of mass screening for untreated atrial fibrillation using intermittent ECG recording
Visa övriga...
2015 (Engelska)Ingår i: Europace, ISSN 1099-5129, E-ISSN 1532-2092, Vol. 17, nr 7, s. 1023-1029Artikel i tidskrift (Refereegranskat) Published
Abstract [en]

Aims The aim of this study was to estimate the cost-effectiveness of 2 weeks of intermittent screening for asymptomatic atrial fibrillation (AF) in 75/76-year-old individuals. Methods and results The cost-effectiveness analysis of screening in 75-year-old individuals was based on a lifelong decision analytic Markov model. In this model, 1000 hypothetical individuals, who matched the population of the STROKESTOP study, were simulated. The population was analysed for different parameters such as prevalence, AF status, treatment with oral anticoagulation, stroke risk, utility, and costs. In the base-case scenario, screening of 1000 individuals resulted in 263 fewer patient-years with undetected AF. This implies eight fewer strokes, 11 more life-years, and 12 more quality-adjusted life years (QALYs) per 1000 screened individuals. The screening implies an incremental cost of (sic)50 012, resulting in a cost of (sic)4313 per gained QALY and (sic)6583 per avoided stroke. Conclusions With the use of a decision analytic simulation model, it has been shown that screening for asymptomatic AF in 75/76-year-old individuals is cost-effective.

Ort, förlag, år, upplaga, sidor
Oxford University Press (OUP): Policy B - Oxford Open Option B - CC-BY, 2015
Nyckelord
Atrial fibrillation; Screening; Hand-held ECG; Quality-adjusted life year ( QALY); Cost-effectiveness
Nationell ämneskategori
Klinisk medicin
Identifikatorer
urn:nbn:se:liu:diva-120879 (URN)10.1093/europace/euv083 (DOI)000359153000006 ()25868469 (PubMedID)
Anmärkning

Funding Agencies|Swedish Heart and Lung Foundation; Board of Benevolence of the Swedish Order of Freemasons; Tornspiran

Tillgänglig från: 2015-08-28 Skapad: 2015-08-28 Senast uppdaterad: 2017-12-04
3. Cost-effectiveness of endovascular thrombectomy in patients with acute ischemic stroke
Öppna denna publikation i ny flik eller fönster >>Cost-effectiveness of endovascular thrombectomy in patients with acute ischemic stroke
Visa övriga...
2016 (Engelska)Ingår i: Neurology, ISSN 0028-3878, E-ISSN 1526-632X, Vol. 86, nr 11, s. 1053-1059Artikel i tidskrift (Refereegranskat) Published
Abstract [en]

OBJECTIVE: To evaluate the cost-effectiveness of adding endovascular thrombectomy to standard care in patients with acute ischemic stroke.

METHODS: The cost-effectiveness analysis of endovascular thrombectomy in patients with acute ischemic stroke was based on a decision-analytic Markov model. Primary outcomes from ESCAPE, Extending the Time for Thrombolysis in Emergency Neurological Deficits-Intra-Arterial (EXTEND-IA), Multicenter Randomized Clinical Trial of Endovascular Treatment for Acute Ischemic Stroke in the Netherlands (MR CLEAN), Endovascular Revascularization With Solitaire Device Versus Best Medical Therapy in Anterior Circulation Stroke Within 8 Hours (REVASCAT), and Solitaire with the Intention for Thrombectomy as Primary Endovascular Treatment for Acute Ischemic Stroke (SWIFT PRIME) along with data from published studies and registries were used in this analysis. We used a health care payer perspective and a lifelong time horizon to estimate costs and effects.

RESULTS: The model showed that adding thrombectomy with stent retrievers to guideline-based care (including IV thrombolysis) resulted in a gain of 0.40 life-years and 0.99 quality-adjusted life-years along with a cost savings of approximately $221 per patient. The sensitivity analysis showed that the results were not sensitive to changes in uncertain parameters or assumptions.

CONCLUSIONS: Adding endovascular treatment to standard care resulted in substantial clinical benefits at low costs. The results were consistent throughout irrespective of whether data from ESCAPE, EXTEND-IA, MR CLEAN, REVASCAT, or SWIFT PRIME were used in this model.

Ort, förlag, år, upplaga, sidor
Lippincott Williams & Wilkins, 2016
Nationell ämneskategori
Hälso- och sjukvårdsorganisation, hälsopolitik och hälsoekonomi
Identifikatorer
urn:nbn:se:liu:diva-126429 (URN)10.1212/WNL.0000000000002439 (DOI)000371887200012 ()26873954 (PubMedID)
Anmärkning

Funding agencies: Dental and Pharmaceutical Benefits Agency

Tillgänglig från: 2016-03-24 Skapad: 2016-03-24 Senast uppdaterad: 2017-11-30
4. Designing an optimal screening program for unknown atrial fibrillation: a cost-effectiveness analysis.
Öppna denna publikation i ny flik eller fönster >>Designing an optimal screening program for unknown atrial fibrillation: a cost-effectiveness analysis.
Visa övriga...
2017 (Engelska)Ingår i: Europace, ISSN 1099-5129, E-ISSN 1532-2092, Vol. 19, nr 10, s. 1650-1656Artikel i tidskrift (Refereegranskat) Published
Abstract [en]

Aims: The primary objective of this study was to use computer simulations to suggest an optimal age for initiation of screening for unknown atrial fibrillation and to evaluate if repeated screening will add value.

Methods and results: In the absence of relevant clinical studies, this analysis was based on a simulation model. More than two billion different designs of screening programs for unknown atrial fibrillation were simulated and analysed. Data from the published scientific literature and registries were used to construct the model and estimate lifelong effects and costs. Costs and effects generated by 2 147 483 648 different screening designs were calculated and compared. Program designs that implied worse clinical outcome and were less cost-effective compared to other programs were excluded from the analysis. Seven program designs were identified, and considered to be cost effective depending on what the health-care decision makers are ready to pay for gaining a quality-adjusted life-year (QALY). Screening at the age of 75 implied the lowest cost per gained QALY (€4 800/QALY).

Conclusion: In conclusion, examining the results of more than two billion simulated screening program designs for unknown atrial fibrillation, seven designs were deemed cost-effective depending on how much we are prepared to pay for gaining QALYs. Our results showed that repeated screening for atrial fibrillation implied additional health benefits to a reasonable cost compared to one-off screening.

Ort, förlag, år, upplaga, sidor
Oxford: Oxford University Press, 2017
Nyckelord
Atrial fibrillation, Cost-utility analysis, Optimization analysis, Screening
Nationell ämneskategori
Hälso- och sjukvårdsorganisation, hälsopolitik och hälsoekonomi
Identifikatorer
urn:nbn:se:liu:diva-141557 (URN)10.1093/europace/eux002 (DOI)000412840300006 ()28340009 (PubMedID)
Anmärkning

Funding agencies: Dental and Pharmaceutical Benefits Agency

Tillgänglig från: 2017-09-29 Skapad: 2017-09-29 Senast uppdaterad: 2017-10-31

Open Access i DiVA

Health Economic Evaluations of Screening Programs - Applications and Method Improvements(1975 kB)231 nedladdningar
Filinformation
Filnamn FULLTEXT02.pdfFilstorlek 1975 kBChecksumma SHA-512
e5a37168e94af24ece328d3d0eaf53b51b286109aa29a7bbffde58c4ab73002dbf38e3e6a0ad6b26d940b09b5a7c915ad539f50bc55b45bcc18f19b0da49c9b0
Typ fulltextMimetyp application/pdf
omslag(1610 kB)6 nedladdningar
Filinformation
Filnamn COVER01.pdfFilstorlek 1610 kBChecksumma SHA-512
005f01c61f89a9a0436e79841da7d51018d6646fe427c093a5adfda353e8ea9da88a2c51f7f88334dffa654607600576ad13b29e7d35ca810d488fdd8b978fa5
Typ coverMimetyp application/pdf

Övriga länkar

Förlagets fulltext

Personposter BETA

Aronsson, Mattias

Sök vidare i DiVA

Av författaren/redaktören
Aronsson, Mattias
Av organisationen
Avdelningen för hälso- och sjukvårdsanalysMedicinska fakulteten
Hälso- och sjukvårdsorganisation, hälsopolitik och hälsoekonomi

Sök vidare utanför DiVA

GoogleGoogle Scholar
Totalt: 235 nedladdningar
Antalet nedladdningar är summan av nedladdningar för alla fulltexter. Det kan inkludera t.ex tidigare versioner som nu inte längre är tillgängliga.

doi
isbn
urn-nbn

Altmetricpoäng

doi
isbn
urn-nbn
Totalt: 556 träffar
RefereraExporteraLänk till posten
Permanent länk

Direktlänk
Referera
Referensformat
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Annat format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annat språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf